

REMARKS

The Examiner has required a Restriction under 35 U.S.C. 121 and 372 between the following groups

Group 1, claims 1-14, drawn to a solid dosage form.

Group II, claims 15-16, drawn to method for treatment.

Group III, claims 17-18, drawn to a use of a solid oral dosage.


Group IV, claims 19-20, drawn to a process for the manufacture of a solid oral dosage.

Applicants elect without traverse Group 1, claims 1-14 drawn to a solid dosage form.

Please elect the species: hypertension. Claims 13 and 14 are readable thereupon.

Examination on the merits is respectfully requested.

Respectfully submitted,



Joseph T. Majka
Attorney for Applicants
Reg. No. 30570

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
Tel. (862) 778-9499

Date: January 26, 2009